MCID: OST003
MIFTS: 66

Osteonecrosis

Categories: Blood diseases, Bone diseases

Aliases & Classifications for Osteonecrosis

Summaries for Osteonecrosis

MedlinePlus : 43 Osteonecrosis is a disease caused by reduced blood flow to bones in the joints. In people with healthy bones, new bone is always replacing old bone. In osteonecrosis, the lack of blood causes the bone to break down faster than the body can make enough new bone. The bone starts to die and may break down. You can have osteonecrosis in one or several bones. It is most common in the upper leg. Other common sites are your upper arm and your knees, shoulders and ankles. The disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties. At first, you might not have any symptoms. As the disease gets worse, you will probably have joint pain that becomes more severe. You may not be able to bend or move the affected joint very well. No one is sure what causes the disease. Risk factors include Long-term steroid treatment Alcohol abuse Joint injuries Having certain diseases, including arthritis and cancer Doctors use imaging tests and other tests to diagnose osteonecrosis. Treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteonecrosis, also known as aseptic necrosis, is related to osteonecrosis of the jaw and legg-calve-perthes disease, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Osteonecrosis is BMP2 (Bone Morphogenetic Protein 2), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and Rheumatoid arthritis. The drugs Alendronate and Zoledronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and testes, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : 12 An ischemic bone disease that results in necrosis located in bone.

Wikipedia : 76 Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to... more...

Related Diseases for Osteonecrosis

Diseases related to Osteonecrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 326)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis of the jaw 33.7 CYP2C8 FDPS VEGFA
2 legg-calve-perthes disease 32.4 COL2A1 SERPINC1 SERPINE1
3 myeloma, multiple 30.8 ABCB1 TNFRSF11B TNFSF11 VEGFA
4 thrombophilia 30.6 F2 MTHFR SERPINC1 SERPINE1
5 osteomyelitis 30.5 ACP5 BMP2 TNFSF11
6 disseminated intravascular coagulation 30.1 F2 SERPINC1 SERPINE1
7 protein s deficiency 30.0 F2 MTHFR SERPINC1
8 kummell's disease 29.9 TNFRSF11B TNFSF11
9 villonodular synovitis 29.9 ACP5 TNFSF11
10 periodontitis 29.9 BGLAP RUNX2 TNFRSF11B TNFSF11
11 renal osteodystrophy 29.9 BGLAP PTH TNFRSF11B
12 osteoporotic fracture 29.8 MTHFR TNFRSF11B
13 antithrombin iii deficiency 29.7 F2 MTHFR SERPINC1
14 protein c deficiency 29.7 F2 MTHFR SERPINC1
15 antiphospholipid syndrome 29.7 F2 MTHFR SERPINC1
16 endosteal hyperostosis, autosomal dominant 29.6 BMP2 TNFRSF11B TNFSF11
17 thrombosis 29.6 F2 MTHFR SERPINC1 SERPINE1
18 giant cell tumor 29.6 BGLAP TNFRSF11B TNFSF11
19 pseudoarthrosis 29.4 BMP2 BMP7 PTH
20 hyperparathyroidism 29.4 ACP5 BGLAP PTH TNFRSF11B
21 vascular disease 29.3 F2 MTHFR SERPINC1 SERPINE1 TNFRSF11B VEGFA
22 bone resorption disease 29.2 ACP5 BGLAP BMP2 PTH RUNX2 TNFRSF11B
23 osteoporosis 29.1 ACP5 BGLAP BMP2 COL2A1 CYP3A4 FDPS
24 paget's disease of bone 29.0 ACP5 BGLAP PTH TNFRSF11B TNFSF11
25 glucocorticoid-induced osteoporosis 28.9 ACP5 BGLAP BMP2 PTH RUNX2 TNFRSF11B
26 bone disease 28.8 ACP5 BGLAP BMP7 COL2A1 PTH RUNX2
27 dysbaric osteonecrosis 12.5
28 avascular necrosis of femoral head, primary, 1 11.7
29 familial avascular necrosis of the femoral head 11.6
30 kohler's disease 11.4
31 freiberg's disease 11.3
32 kienbock's disease 11.3
33 osgood-schlatter's disease 11.2
34 panner disease 11.2
35 sinding-larsen-johansson disease 11.2
36 thiemann disease 11.0
37 gaucher disease, type iii 11.0
38 systemic lupus erythematosus 10.4
39 lymphocytic leukemia 10.4
40 lupus erythematosus 10.4
41 leukemia 10.4
42 leukemia, acute lymphoblastic 10.4
43 arthritis 10.3
44 inferior vena cava interruption 10.3 MTHFR SERPINE1
45 breast cancer 10.3
46 prostate cancer 10.3
47 neonatal stroke 10.3 MTHFR SERPINE1
48 amaurosis fugax 10.3 MTHFR SERPINE1
49 hemifacial spasm 10.3 MTHFR VEGFA
50 mesenteric vascular occlusion 10.3 F2 MTHFR

Graphical network of the top 20 diseases related to Osteonecrosis:



Diseases related to Osteonecrosis

Symptoms & Phenotypes for Osteonecrosis

UMLS symptoms related to Osteonecrosis:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Osteonecrosis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.26 ABCB1 BMP2 BMP7 COL2A1 F2 PTH
2 growth/size/body region MP:0005378 10.26 ABCB1 BMP2 BMP7 COL2A1 F2 MTHFR
3 hematopoietic system MP:0005397 10.2 ABCB1 BMP2 BMP7 F2 PTH RUNX2
4 immune system MP:0005387 10.18 ABCB1 BMP2 BMP7 COL2A1 F2 PTH
5 homeostasis/metabolism MP:0005376 10.17 ABCB1 BMP2 COL2A1 F2 MTHFR PTH
6 craniofacial MP:0005382 10.11 BMP2 BMP7 COL2A1 PTH RUNX2 TNFRSF11B
7 mortality/aging MP:0010768 10.07 ABCB1 BMP2 BMP7 COL2A1 F2 MTHFR
8 digestive/alimentary MP:0005381 10.04 ABCB1 BMP2 BMP7 COL2A1 F2 RUNX2
9 limbs/digits/tail MP:0005371 10.02 BMP2 BMP7 COL2A1 MTHFR PTH RUNX2
10 liver/biliary system MP:0005370 9.87 ABCB1 COL2A1 MTHFR RUNX2 SERPINC1 SERPINE1
11 reproductive system MP:0005389 9.81 ABCB1 BMP2 BMP7 F2 MTHFR RUNX2
12 respiratory system MP:0005388 9.5 BMP7 COL2A1 F2 RUNX2 SERPINE1 TNFSF11
13 skeleton MP:0005390 9.32 BMP2 BMP7 COL2A1 F2 MTHFR PTH

Drugs & Therapeutics for Osteonecrosis

Drugs for Osteonecrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2,Phase 1 66376-36-1, 121268-17-5 2088
2
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
3
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
4
Tocopherol Approved, Investigational Phase 4,Phase 3 1406-66-2 14986
5
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
6
Enoxaparin Approved Phase 4 9005-49-6 772
7
Rivaroxaban Approved Phase 4 366789-02-8
8
Dalteparin Approved Phase 4 9005-49-6
9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
10
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
11
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
12 Tocotrienol Investigational Phase 4,Phase 3 6829-55-6
13 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
16 Anesthetics Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
17 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
19 Phosphodiesterase Inhibitors Phase 4,Phase 3
20 Vasodilator Agents Phase 4,Phase 3
21 Free Radical Scavengers Phase 4,Phase 3
22 Tocotrienols Phase 4,Phase 3
23 Trace Elements Phase 4,Phase 3,Phase 2
24 Micronutrients Phase 4,Phase 3,Phase 2
25 Radiation-Protective Agents Phase 4,Phase 3
26 Tocopherols Phase 4,Phase 3
27 Platelet Aggregation Inhibitors Phase 4,Phase 3
28 Antioxidants Phase 4,Phase 3
29 Protective Agents Phase 4,Phase 3
30
protease inhibitors Phase 4
31 calcium heparin Phase 4
32 Factor Xa Inhibitors Phase 4
33 Heparin, Low-Molecular-Weight Phase 4
34 Anticoagulants Phase 4
35 Antithrombins Phase 4
36 Antithrombin III Phase 4
37 HIV Protease Inhibitors Phase 4
38 Serine Proteinase Inhibitors Phase 4
39 Pharmaceutical Solutions Phase 4,Phase 2,Not Applicable
40 Hematinics Phase 4,Not Applicable
41 Ferrosoferric Oxide Phase 4,Not Applicable
42 Parenteral Nutrition Solutions Phase 4,Not Applicable
43 Adjuvants, Immunologic Phase 4
44 Viscosupplements Phase 4
45
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
46
Fludarabine Approved Phase 3 75607-67-9, 21679-14-1 30751
47
Etoposide Approved Phase 3 33419-42-0 36462
48
Denosumab Approved Phase 3,Phase 1,Phase 2 615258-40-7
49
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
50
Gemcitabine Approved Phase 3 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 201)
# Name Status NCT ID Phase Drugs
1 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis Unknown status NCT00265252 Phase 4 Alendronate
2 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
3 Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings Completed NCT01806766 Phase 4
4 A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients Completed NCT01345097 Phase 4
5 Ultra-Short Anatomic and Conventional Cementless Stems Cementless Stems in Patients Younger Than Fifty-Five Years Old Completed NCT02338596 Phase 4
6 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed NCT02139007 Phase 4 Alendronate
7 Management of Mandibular ORN: PENTO as Medical Treatment Completed NCT02368457 Phase 4 Pentoxifylline and Tocopherol
8 Ceramic-on-Ceramic Versus Ceramic-on-HXLPE THA Completed NCT03639532 Phase 4
9 Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty Completed NCT02379663 Phase 4 Rivaroxaban;Enoxaparin
10 Benefit of Orthopedic Navigation in the ARThroplasty of the Hip Completed NCT01496300 Phase 4
11 Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI Recruiting NCT02893293 Phase 4 Ferumoxytol-enhanced magnetic resonance imaging
12 Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis Recruiting NCT02984228 Phase 4 Hyaluronic Acid
13 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
14 Optetrak Posterior Stabilized Versus Optetrak Hi-Flex Withdrawn NCT00808613 Phase 4
15 Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH) Unknown status NCT01613612 Phase 2, Phase 3
16 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
17 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
18 Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head Completed NCT00505219 Phase 3
19 Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial Completed NCT00532220 Phase 3 Ibandronate IV;Placebo
20 Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head Completed NCT00939900 Phase 3 zoledronic acid (aclasta)
21 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis Completed NCT00523341 Phase 3
22 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Completed NCT00869206 Phase 3 zoledronic acid
23 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
24 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
25 Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee. Completed NCT02709486 Phase 3 Tanezumab;Tanezumab;Placebo
26 N-Acetylcysteine in Patients With Sickle Cell Disease Completed NCT01849016 Phase 3 N-Acetylcysteine;Placebo
27 Aspirin in the Prevention of Collapse in Osteonecrosis of the Hip Recruiting NCT03405974 Phase 3 Aspirin;Placebo
28 Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head Recruiting NCT01529008 Phase 3 Core decompression/PREOB® implantation;Core decompression/placebo implantation
29 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ) Recruiting NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
30 Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Recruiting NCT02684708 Phase 3 cyclophosphamide, vincristine, prednisone, dacarbazine;cyclo, vcr, pred, dacarb,etop and doxo
31 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Recruiting NCT02051218 Phase 3 Denosumab (reduced dosing);Denosumab (standard dosing)
32 Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies Recruiting NCT03408652 Phase 3 denosumab
33 Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy. Recruiting NCT02609828 Phase 3 Tanezumab
34 Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head Active, not recruiting NCT01892514 Phase 3
35 ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee Active, not recruiting NCT01458782 Phase 2, Phase 3
36 Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2) Active, not recruiting NCT01908751 Phase 3 Vitamin D;Vitamin D Placebo
37 Study of Skeletal Response to Eliglustat in Patients With Gaucher Disease Enrolling by invitation NCT02536755 Phase 3 eliglustat GZ385660
38 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw Not yet recruiting NCT03390777 Phase 2, Phase 3
39 Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis Terminated NCT02114489 Phase 3 ibandronate;Placebo
40 Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma Terminated NCT02739594 Phase 3 Ibandronate;Zoledronate
41 A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement Terminated NCT00208468 Phase 3
42 Osteonecrosis of the Hip and Bisphosphonate Treatment Unknown status NCT00781261 Phase 2 Zoledronic Acid;Placebo
43 MBCP Safety and Performance in the Osteonecrosis of Femur Head Unknown status NCT00289575 Phase 2
44 PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells Completed NCT01700920 Phase 2
45 Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head Completed NCT02890537 Phase 2 Core decompression/PREOB® implantation;Core decompression/BMC implantation
46 Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty Completed NCT01622465 Phase 2
47 Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents Completed NCT00921557 Phase 2 Alendronate;Placebo
48 Shock Wave Therapy for Osteoporosis Completed NCT02630381 Phase 2
49 MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) Completed NCT00996801 Phase 2 MK-5442;Placebo to MK-5442;Alendronate Sodium;Vitamin D3;Calcium carbonate;Placebo to Alendronate
50 Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers Completed NCT01367288 Phase 2 Zometa + Neoadjuvant therapy;Neoadjuvant therapy

Search NIH Clinical Center for Osteonecrosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteonecrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteonecrosis:
JACC�, cultured cartilage for chondral lesion
PREOB�, autologous osteoblasts for bone disorders
Embryonic/Adult Cultured Cells Related to Osteonecrosis:
Cultured cartilage (JACC�) PMIDs: 16233778 19393556 10738867 16226641 11284883 12043781 16233853 19802670 10679677

Cochrane evidence based reviews: osteonecrosis

Genetic Tests for Osteonecrosis

Genetic tests related to Osteonecrosis:

# Genetic test Affiliating Genes
1 Aseptic Necrosis 29

Anatomical Context for Osteonecrosis

MalaCards organs/tissues related to Osteonecrosis:

41
Bone, Bone Marrow, Testes, Breast, Endothelial, Prostate, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Osteonecrosis:

19
Bone

Publications for Osteonecrosis

Articles related to Osteonecrosis:

(show top 50) (show all 2582)
# Title Authors Year
1
Severe bilateral knee osteonecrosis in a young man with human immunodeficiency virus. ( 30425776 )
2019
2
MiR-217 promotes cell proliferation and osteogenic differentiation of BMSCs by targeting DKK1 in steroid-associated osteonecrosis. ( 30551361 )
2019
3
Osteonecrosis in children with acute lymphoblastic leukemia: A report from Children's Cancer Hospital Egypt (CCHE). ( 30183135 )
2019
4
Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. ( 29955628 )
2018
5
Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. ( 29360413 )
2018
6
Comment on: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29799056 )
2018
7
Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review. ( 29977926 )
2018
8
Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia: two and a half to fourteenA year follow-up. ( 29594456 )
2018
9
Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. ( 29941400 )
2018
10
Association of common comorbidities with osteonecrosis: a nationwide population-based case-control study in Denmark. ( 29439082 )
2018
11
Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. ( 29211870 )
2018
12
Short stem survival after osteonecrosis of the femoral head. ( 29396635 )
2018
13
Enhanced bone defect repairing effects in glucocorticoid-induced osteonecrosis of the femoral head using a porous nano-lithium-hydroxyapatite/gelatin microsphere/erythropoietin composite scaffold. ( 29369309 )
2018
14
Development of antiresorptive agent-related osteonecrosis of the jaw after dental implant removal: a case report. ( 29870295 )
2018
15
Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA-compliant meta-analysis of animal studies and clinical trials. ( 29362430 )
2018
16
Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. ( 29729428 )
2018
17
Early removal of sequestrum in patients affected by medication-related osteonecrosis of the jaw. ( 29422306 )
2018
18
Machine learning to predict the occurrence of bisphosphonate-related osteonecrosis of the jaw associated with dental extraction: A preliminary report. ( 29698784 )
2018
19
The biological basis for concentrated iliac crest aspirate to enhance core decompression in the treatment of osteonecrosis. ( 29435623 )
2018
20
Th17 and IL-17 exhibit higher levels in osteonecrosis of the femoral head and have a positive correlation with severity of pain. ( 29952419 )
2018
21
Correction to : Hip osteonecrosis: stem cells for life or behead and arthroplasty? ( 29934718 )
2018
22
Diving, Dysbaric Osteonecrosis ( 29493935 )
2018
23
Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. ( 29802059 )
2018
24
Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics. ( 29325851 )
2018
25
Recommendations for the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Systematic Review. ( 29747794 )
2018
26
Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-NaA^ve Patient: A Comprehensive Review of the Literature. ( 29850569 )
2018
27
Pyogenic arthritis pyoderma gangrenosum and acne syndrome: A rare but important diagnosis for antibiotic-resistant erysipelas-like erythema and osteonecrosis. ( 29943877 )
2018
28
Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223. ( 29861164 )
2018
29
Thrombophilia-Associated Factors in Patients with Spontaneous Osteonecrosis of the Knee. ( 29308659 )
2018
30
Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions. ( 29432652 )
2018
31
Accuracy of MRI diagnosis of early osteonecrosis of the femoral head: a meta-analysis and systematic review. ( 29973239 )
2018
32
Comment on "Nasolabial Flap Improves Healing in Medication-Related Osteonecrosis of the Jaw" by Lemound etA al. ( 29902417 )
2018
33
The association with xerostomia from sialadenitis and the jaw osteonecrosis in head and neck cancer population: a nationwide cohort study. ( 29725850 )
2018
34
Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis. ( 29289789 )
2018
35
FGF2 and FAM201A affect the development of osteonecrosis of the femoral head after femoral neck fracture. ( 29382571 )
2018
36
Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. ( 29408511 )
2018
37
Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. ( 29943905 )
2018
38
Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? ( 29860712 )
2018
39
Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5A years of experience. ( 29948937 )
2018
40
A new 3D printed titanium metal trabecular bone reconstruction system for early osteonecrosis of the femoral head. ( 29952948 )
2018
41
Vitamin D supplementation: Hypothetical effect on medication-related osteonecrosis of the jaw. ( 29857915 )
2018
42
The role of the subchondral layer in osteonecrosis of the femoral head: analysis based on HR-QCT in comparison to MRI findings. ( 29979104 )
2018
43
Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. ( 29713913 )
2018
44
High-energy extracorporeal shock wave therapy for nontraumatic osteonecrosis of the femoral head. ( 29394948 )
2018
45
Auto-Fluorescence and Histopathologic Evaluation of Medication-Related Osteonecrosis of the Jaws: Perspectives for Treatment. ( 29944562 )
2018
46
Authors' reply: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29796683 )
2018
47
Extravascular Hydrophobic Surfaces, Fat Droplets, and the Connection With Decompression Illness: Spinal, Joint Pain, and Dysbaric Osteonecrosis. ( 29636703 )
2018
48
Medication-related osteonecrosis of the jaw, osteoradionecrosis, and osteomyelitis: A comparative histopathological study. ( 29723337 )
2018
49
The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. ( 29694412 )
2018
50
Duration of treatment with bisphosphonates at the time of osteonecrosis of the jaw onset in patients with rheumatoid arthritis. Review. ( 29325766 )
2018

Variations for Osteonecrosis

Expression for Osteonecrosis

Search GEO for disease gene expression data for Osteonecrosis.

Pathways for Osteonecrosis

Pathways related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1 11.78 BGLAP PTH RUNX2 TNFSF11
2 11.71 ACP5 TNFSF11 VEGFA
3
Show member pathways
11.68 ABCB1 CYP2C8 CYP3A4
4
Show member pathways
11.61 ABCB1 CYP2C8 CYP3A4
5
Show member pathways
11.57 ABCB1 CYP2C8 CYP3A4
6
Show member pathways
11.56 BMP2 BMP7 RUNX2
7 11.5 ABCB1 SERPINE1 VEGFA
8
Show member pathways
11.48 ABCB1 CYP2C8 CYP3A4
9
Show member pathways
11.39 ABCB1 CYP2C8 CYP3A4
10 11.37 BMP7 COL2A1 PTH RUNX2 VEGFA
11 11.15 BGLAP PTH RUNX2 TNFSF11
12
Show member pathways
10.99 ABCB1 CYP2C8 CYP3A4
13 10.83 ABCB1 CYP3A4
14 10.78 ACP5 TNFRSF11B TNFSF11
15 10.77 ABCB1 CYP3A4
16 10.76 BGLAP F2
17 10.75 BGLAP CYP3A4 PTH RUNX2 TNFRSF11B TNFSF11
18 10.72 ABCB1 CYP2C8 CYP3A4
19 10.61 ABCB1 CYP2C8 CYP3A4
20 10.56 ABCB1 CYP3A4
21 10.4 BGLAP PTH TNFRSF11B TNFSF11

GO Terms for Osteonecrosis

Cellular components related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 BGLAP BMP2 BMP7 COL2A1 F2 PTH
2 endoplasmic reticulum lumen GO:0005788 9.56 BGLAP COL2A1 F2 SERPINC1
3 collagen-containing extracellular matrix GO:0062023 9.46 BMP7 COL2A1 SERPINC1 SERPINE1
4 extracellular space GO:0005615 9.36 BGLAP BMP2 BMP7 COL2A1 F2 PTH

Biological processes related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 BMP2 BMP7 RUNX2 TNFSF11 VEGFA
2 animal organ morphogenesis GO:0009887 9.84 BMP2 BMP7 TNFSF11
3 steroid metabolic process GO:0008202 9.84 CYP2C8 CYP3A4 FDPS
4 osteoblast differentiation GO:0001649 9.83 BGLAP BMP2 RUNX2
5 response to drug GO:0042493 9.83 ABCB1 BGLAP MTHFR PTH TNFRSF11B
6 BMP signaling pathway GO:0030509 9.8 BMP2 BMP7 RUNX2
7 cartilage development GO:0051216 9.78 BMP2 BMP7 COL2A1
8 regulation of signaling receptor activity GO:0010469 9.76 BMP2 BMP7 F2 PTH SERPINE1 TNFRSF11B
9 positive regulation of osteoblast differentiation GO:0045669 9.75 BMP2 BMP7 RUNX2
10 odontogenesis of dentin-containing tooth GO:0042475 9.73 BMP2 BMP7 RUNX2
11 bone development GO:0060348 9.7 BGLAP COL2A1 TNFSF11
12 mammary gland alveolus development GO:0060749 9.66 TNFSF11 VEGFA
13 regulation of osteoclast differentiation GO:0045670 9.65 BGLAP TNFSF11
14 positive regulation of ossification GO:0045778 9.65 BMP2 PTH
15 bone mineralization GO:0030282 9.65 BGLAP BMP2 PTH
16 positive regulation of blood coagulation GO:0030194 9.64 F2 SERPINE1
17 regulation of blood coagulation GO:0030193 9.64 F2 SERPINC1
18 response to inorganic substance GO:0010035 9.63 BGLAP TNFRSF11B
19 chondrocyte differentiation GO:0002062 9.63 BMP2 COL2A1 RUNX2
20 embryonic skeletal joint morphogenesis GO:0060272 9.62 BMP7 COL2A1
21 mesenchymal cell differentiation GO:0048762 9.62 BMP2 BMP7
22 negative regulation of fibrinolysis GO:0051918 9.61 F2 SERPINE1
23 oxidative demethylation GO:0070989 9.6 CYP2C8 CYP3A4
24 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.59 BMP2 RUNX2
25 proteoglycan metabolic process GO:0006029 9.58 BMP2 COL2A1
26 positive regulation of bone mineralization GO:0030501 9.58 BMP2 BMP7 PTH
27 cellular response to BMP stimulus GO:0071773 9.56 BMP2 BMP7 COL2A1 RUNX2
28 lipid hydroxylation GO:0002933 9.55 CYP2C8 CYP3A4
29 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.54 BMP2 RUNX2
30 bone resorption GO:0045453 9.54 ACP5 PTH TNFSF11
31 response to vitamin D GO:0033280 9.5 BGLAP BMP7 PTH
32 skeletal system development GO:0001501 9.5 BGLAP BMP2 BMP7 COL2A1 PTH RUNX2
33 mesenchyme development GO:0060485 9.49 BMP2 BMP7
34 ossification GO:0001503 9.17 ACP5 BGLAP BMP2 BMP7 COL2A1 RUNX2
35 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 BMP2 BMP7 PTH RUNX2 SERPINE1 TNFSF11

Molecular functions related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 BMP2 BMP7 F2 VEGFA
2 heparin binding GO:0008201 9.46 BMP7 F2 SERPINC1 VEGFA
3 BMP receptor binding GO:0070700 9.37 BMP2 BMP7
4 estrogen 16-alpha-hydroxylase activity GO:0101020 9.32 CYP2C8 CYP3A4
5 cytokine activity GO:0005125 9.02 BMP2 BMP7 TNFRSF11B TNFSF11 VEGFA
6 caffeine oxidase activity GO:0034875 8.96 CYP2C8 CYP3A4

Sources for Osteonecrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....